MiniMed Group
MMED
19.11
-0.53
-2.70%
MiniMed Group
US · MMED
#2009 by market cap
Listed 2026
19.11
-0.53
-2.70%
Live - 5344 symbols - heartbeat 503s ago
· 2026-10-08 07:30
Pre-market
18.99
-0.63%
After-hours
19.18
+0.37%
Overnight
19.00
-0.58%
- Market cap
- 5.38B
- P/E (TTM)i
- -16.96
- P/Bi
- 1.49
- EPSi
- -1.30
- Div yieldi
- 0.00%
- 52W posi
- 61%
Reader sentiment
Are you bullish or bearish on MMED?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.85, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Latest year +14.25% YoY
Margins
- Gross margin
- 54.16%
- Operating margin
- -5.13%
- Net margin
- -10.74%
Key ratios & quality
- Altman Z-Scorei
- 3.85
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Revenue | 2.25B | 2.47B | 2.72B | 3.10B |
| Gross profit | 1.31B | 1.44B | 1.53B | 1.68B |
| Selling & admin expenses | 960.00M | 1.06B | 1.08B | 1.18B |
| Research & development | 429.00M | 437.00M | 436.00M | 448.00M |
| Operating profit | -69.00M | -61.00M | 33.00M | -159.00M |
| Pretax profit | -76.00M | -70.00M | -147.00M | -189.00M |
| Tax | 16.00M | 38.00M | 52.00M | 128.00M |
| Net profit | -92.00M | -107.00M | -198.00M | -317.00M |
| Basic EPS | 0 | 0 | -1 | -1 |
| Diluted EPS | -0.34 | -0.40 | -0.76 | -1.30 |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Revenue | 724.00M | 723.00M | 752.00M | 790.00M | 837.00M | 843.00M |
| Gross profit | 405.00M | 409.00M | 428.00M | 362.00M | 480.00M | 465.00M |
| Selling & admin expenses | 276.00M | 283.00M | 318.00M | 309.00M | 299.00M | 312.00M |
| Research & development | 107.00M | 125.00M | 111.00M | 114.00M | 99.00M | 115.00M |
| Operating profit | 31.00M | 3.00M | -10.00M | -93.00M | -87.00M | 2.00M |
| Pretax profit | -148.00M | -13.00M | -12.00M | -99.00M | -92.00M | 4.00M |
| Tax | 21.00M | 3.00M | 19.00M | 12.00M | 93.00M | 4.00M |
| Net profit | -168.00M | -16.00M | -30.00M | -111.00M | -185.00M | 0 |
| Basic EPS | -1 | 0 | 0 | 0 | -1 | 0 |
| Diluted EPS | -0.61 | -0.07 | -0.10 | -0.42 | -0.66 | 0.00 |
Balance sheet
| Line item | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Total current assets | -- | 895.00M | 939.00M | 1.35B |
| Cash & ST investments | -- | 54.00M | 11.00M | 298.00M |
| Inventory | -- | 292.00M | 310.00M | 341.00M |
| Total assets | -- | 4.09B | 4.20B | 4.63B |
| Total current liabilities | -- | 518.00M | 710.00M | 702.00M |
| Short-term debt | -- | 8.00M | 11.00M | 145.00M |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | -- | 646,000,000.00 | 870,000,000.00 | 1,019,000,000.00 |
| Total equity | -- | 3.45B | 3.33B | 3.61B |
| Retained earnings | -- | -- | 0 | -116.00M |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Total current assets | 939.00M | -- | 891.00M | 1.11B | 1.35B | 1.42B |
| Cash & ST investments | 11.00M | -- | 350.00M | 10.00M | 298.00M | 207.00M |
| Inventory | 310.00M | -- | 362.00M | 407.00M | 341.00M | 356.00M |
| Total assets | 4.20B | -- | 4.24B | 4.34B | 4.63B | 4.72B |
| Total current liabilities | 710.00M | -- | 350.00M | 696.00M | 702.00M | 782.00M |
| Short-term debt | 11.00M | -- | -- | 11.00M | 145.00M | 9.00M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 870,000,000.00 | -- | 491,000,000.00 | 880,000,000.00 | 1,019,000,000.00 | 1,098,000,000.00 |
| Total equity | 3.33B | -- | 3.74B | 3.46B | 3.61B | 3.62B |
| Retained earnings | 0 | -- | -5.00M | -- | -116.00M | -116.00M |
Cash flow
| Line item | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Operating cash flow | -6.00M | 41.00M | 140.00M | -197.00M |
| Depreciation & amortization | 115.00M | 129.00M | 143.00M | 156.00M |
| Free cash flow | -173.00M | -107.00M | -53.00M | -420.00M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 0 | 538.00M |
| Ending cash balance | 58.00M | 54.00M | 11.00M | 298.00M |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Operating cash flow | 83.00M | -141.00M | 48.00M | 66.00M | -170.00M | -49.00M |
| Depreciation & amortization | 38.00M | 39.00M | 39.00M | 39.00M | 39.00M | 41.00M |
| Free cash flow | 26.00M | -194.00M | -13.00M | 13.00M | -226.00M | -90.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 11.00M | 9.00M | 8.00M | 10.00M | 298.00M | 207.00M |
Returns & efficiency
| Line item | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| ROE %i | -- | -3.25 | -7.38 | -9.59 |
| ROA %i | -- | -2.74 | -6.03 | -7.54 |
| ROIC %i | -- | -3.24 | -7.36 | -9.38 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -3.07 | -2.47 | -1.33 | -5.13 |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | -- | 1.73 | 1.32 | 1.92 |
| Quick ratioi | -- | 1.08 | 0.82 | 1.36 |
| Debt / assetsi | -- | 0.20 | 0.26 | 3.13 |
| LT debt / equityi | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 11.38 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| ROE %i | -7.38 | -- | -7.08 | -10.31 | -9.59 | -8.67 |
| ROA %i | -6.03 | -- | -6.26 | -8.22 | -7.54 | -6.66 |
| ROIC %i | -7.36 | -- | -7.08 | -10.28 | -9.38 | -8.65 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -1.33 | -- | -0.80 | -3.68 | -5.13 | -4.97 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.32 | -- | 2.55 | 1.59 | 1.92 | 1.81 |
| Quick ratioi | 0.82 | -- | 1.47 | 0.95 | 1.36 | 1.26 |
| Debt / assetsi | 0.26 | -- | -- | 0.25 | 3.13 | 0.19 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Continuous glucose monitoring (CGM) is the largest reported line at 51.13% of revenue, across 4 reported segments.
- Consumables follows at 30.96%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Continuous glucose monitoring (CGM)51.13%
Consumables30.96%
Pumps17.08%
Other0.83%
Quote time 2026-10-08 07:30:57 · For reference only, not investment advice and not tailored to your situation.